Abstract:The oral glucose tolerance test is still the definitive test for diagnosing diabetes mellitus, although the diagnosis can be made without the test when the patient has typical features of the disease and a raised plasma glucose concentration. Many glucose tolerance tests are carried out in hospitals, with the average hospital laboratory performing about five a week (with considerable variation between individual hospitals).' Nevertheless, despite recent attempts to try to standardise the procedure for both performing and interpreting the test,2-5 a recent survey has shown that agreed protocols, such as that of the World Health Organisation expert committee,3'5 are not always followed. As an example, the World Health Organisation specifies a fasting period of 10 to 16 hours.5 Most ofthe respondents to a questionnaire sent out by a working party of the Association of Clinical Biochemists said that they fasted patients for between nine and 14 hours, but a tenth simply asked patients to fast "overnight" and a few asked them to fast for as little as five hours. Previous carbohydrate intake may also influence the glycaemic response and an unrestricted diet containing at least 150 g of carbohydrate a day is advised for the three days before the test.5 Nevertheless, most laboratories assumed that this was the case without actually specifying it. Over four fifths of hospitals were using the currently recommended 75 g load of glucose,5 but the remainder were using 50 g. Another difference in approach is the type of glucose used. The World Health Organisation recommends using 75 g of glucose but does not say whether this is anhydrous glucose or the monohydrate; hence some centres are using one form and some the other, with a resultant difference of about 10% in the actual load ofglucose given. Though this discrepancy in a total dose ofabout 75 g may not evoke much difference in the blood sugar response, it is an undesirable and avoidable potential source ofvariation. As the monohydrate is the most readily available form, it would seem sensible to standardise on this. Again, about a fifth of laboratories used proprietary liquid preparations of partially hydrolysed starch (such as Lucozade), but sometimes the volume used differed from that recommended. The World Health Organisation criteria for interpreting the results ofthe glucose tolerance test vary depending on the type of specimen used-for example venous whole blood, venous plasma, or capillary whole blood. The 1980 World Health Organisation report gave no figures for capillary plasma,3 which was used by a tenth of the participants in the survey and will in some instances yield higher results than venous plasma. The 1985 World Health Organisation report does, however, include figures for capillary plasma,5 but probably many laboratory staff and clinicians are still unaware of the more recent document. Clearly when interpreting the results ofa glucose tolerance test the doctor must know about such influencing factors and what protocol was used. Failure to pay attention to this type of detail might lead to a patient being incorrectly classified as a diabetic, with lifelong consequences-medical, social, legal, and financial. A degree of glucose tolerance intermediate between normality and diabetes, termed "impaired glucose tolerance," does not necessarily foreshadow diabetes, and indeed may revert to normal; hence it should not be regarded in the same way as a diagnosis of definite diabetes. The results of glucose tolerance tests are often reported without any comment to clinicians. Even if they are familiar with theWorld Health Organisation criteria for classification, they may not know the details of their own laboratory's procedure and hence may misinterpret the results using the wrong set of figures. Such a pitfall may be avoided by closer cooperation between the laboratory and the clinician. The laboratory should be able to offer an interpretation or at least to advise on the best criteria to use; if this information is not volunteered the clinician should ask for it. K WIENER

Food as a Hormone

Two Approaches towards the Formalisation of VDM

Simultaneous Quantification of Antidepressants and Metabolites in Urine and Plasma Samples by GC–MS for Therapeutic Drug Monitoring

Evaluation of 4 quantification methods for monitoring 16 antidepressant drugs and their metabolites in human plasma by LC-MS/MS

Despeckling of Ultrasound Medical Images: A Survey

An in-depth analysis of four classes of antidepressants quantification from human serum using LC-MS/MS

Diagnosis of diabetes mellitus: pitfalls in the glucose tolerance test.

High-performance liquid chromatography-tandem mass spectrometry was used to measure 20 antidepressants in human serum

Direct Immersion–Solid Phase Microextraction for Therapeutic Drug Monitoring of Patients with Mood Disorders

Pipette-tip solid-phase extraction coupled with matrix-assisted laser desorption/ionization mass spectrometry enables rapid and high-throughput analysis of antidepressants in rat serum

Safety and efficacy of a high-adhesion whitening strip under extended wear regimen.

Sensitive and Fast Detection of Monoamines and Their Metabolites by High-Performance Liquid Chromatography Coupled with an Electrochemical Detector (HPLC-ECD) Under Isocratic Conditions: Application to Intracerebral Microdialysis in Mice Treated by Fluoxetine and Atomoxetine

New qualitative methods for stability of delay systems

Comparison of Various Chromatographic Systems for Identification of Vortioxetine in Bulk Drug Substance, Human Serum, Saliva, and Urine Samples by HPLC-DAD and LC-QTOF-MS

Determination of antidepressants in whole blood using hollow-fiber liquid-phase microextraction and gas chromatography–mass spectrometry

A Sensitive and Practical RP-HPLC-FLD for Determination of the Low Neuroactive Amino Acid Levels in Body Fluids and Its Application in Depression

High-Throughput Liquid Chromatography- Vacuum Differential Mobility Spectrometry-Mass Spectrometry for the Analysis of Isomeric Drugs of Abuse in Human Urine

Simultaneous Quantification Of 38 Psychotropic Drugs And Relevant Metabolites In Blood Using Lc-Ms-Ms

Hollow-fiber liquid phase microextraction for determination of fluoxetine in human serum by nano-liquid chromatography coupled to high resolution mass spectrometry

Efficient dispersive micro solid-phase extraction of antidepressant drugs by a robust molybdenum-based coordination polymer

Quantitative determination of fifteen basic pharmaceuticals in ante- and post-mortem whole blood by high pH mobile phase reversed phase ultra high performance liquid chromatography-tandem mass spectrometry